Cargando…

Pharmacokinetics and pharmacodynamics of fenoldopam mesylate for blood pressure control in pediatric patients

BACKGROUND: Fenoldopam mesylate, a selective dopamine1-receptor agonist, is used by intravenous infusion to treat hypertension in adults. Fenoldopam is not approved by the FDA for use in children; reports describing its use in pediatrics are limited. In a multi-institutional, placebo controlled, dou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hammer, Gregory B, Verghese, Susan T, Drover, David R, Yaster, Myron, Tobin, Joseph R
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2576052/ https://www.ncbi.nlm.nih.gov/pubmed/18837982 http://dx.doi.org/10.1186/1471-2253-8-6

Ejemplares similares

Fenoldopam Mesylate: A Narrative Review of Its Use in Acute Kidney Injury
por: Noce, Annalisa, et al.
Publicado: (2019)

Fenoldopam Mesylate Enhances the Survival of Mesenchymal Stem Cells Under Oxidative Stress and Increases the Therapeutic Function in Acute Kidney Injury
por: Jo, Seo Yeon, et al.
Publicado: (2023)

Renal protection in the ICU: role of fenoldopam
por: Bertini, P, et al.
Publicado: (2008)

Synthesis, Characterization, and Pharmacodynamics Study of Enrofloxacin Mesylate
por: Pei, Lin-lin, et al.
Publicado: (2020)

Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19
por: Kosinsky, Yuri, et al.
Publicado: (2022)

Periferic intravenous infusion of fenoldopam through an elastomeric pump
por: Quaranta, T, et al.
Publicado: (2009)

Population pharmacokinetics of remifentanil in infants and children undergoing cardiac surgery
por: Sam, Wai Johnn, et al.
Publicado: (2009)

Fenoldopam Increases Urine Output in Oliguric Critically Ill Surgical Patients
por: Cagliani, Joaquin A, et al.
Publicado: (2021)

Fenoldopam use in a burn intensive care unit: a retrospective study
por: Simmons, John W, et al.
Publicado: (2010)

Detection of fenoldopam-induced arteritis in rats using ex vivo / in vivo MRI
por: Fujii, Yuta, et al.
Publicado: (2022)

Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS
por: Ghezzi, Angelo, et al.
Publicado: (2019)

Evaluation of Pharmacokinetics and Pharmacodynamics of Deferasirox in Pediatric Patients
por: Galeotti, Laura, et al.
Publicado: (2021)

Pharmacokinetic–Pharmacodynamic Modeling of Midazolam in Pediatric Surgery
por: Flores-Pérez, Carmen, et al.
Publicado: (2023)

High-dose fenoldopam reduces postoperative neutrophil gelatinase-associated lipocaline and cystatin C levels in pediatric cardiac surgery
por: Ricci, Zaccaria, et al.
Publicado: (2011)

Proton Pump Inhibitors in Pediatrics: Mechanism of Action, Pharmacokinetics, Pharmacogenetics, and Pharmacodynamics
por: Ward, Robert M., et al.
Publicado: (2013)

Fenoldopam to prevent renal replacement therapy after cardiac surgery. Design of the FENO-HSR study
por: Landoni, G, et al.
Publicado: (2010)

Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J., et al.
Publicado: (2022)

Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics
por: Quinn, Tom M., et al.
Publicado: (2022)

Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function
por: Tan, Antoinette R., et al.
Publicado: (2015)

Effect of Fenoldopam Continuous Infusion on Glomerular Filtration Rate and Fractional Excretion of Sodium in Healthy Dogs
por: Kelly, K.L., et al.
Publicado: (2016)

Clinical Pharmacokinetics and Pharmacodynamics of Propofol
por: Sahinovic, Marko M., et al.
Publicado: (2018)

Clinical Pharmacokinetics and Pharmacodynamics of Dexmedetomidine
por: Weerink, Maud A. S., et al.
Publicado: (2017)

Pharmacokinetic–Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance
por: Germovsek, Eva, et al.
Publicado: (2018)

Population pharmacokinetics–pharmacodynamics of sunitinib in pediatric patients with solid tumors
por: Wang, Erjian, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Posaconazole
por: Chen, Lu, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Ibrexafungerp
por: McCarthy, Matthew William
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Tedizolid
por: Iqbal, Khalid, et al.
Publicado: (2022)

Fenoldopam to prevent acute kidney injury after major surgery—a systematic review and meta-analysis
por: Gillies, Michael A., et al.
Publicado: (2015)

Correction to: Pharmacokinetic–Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance
por: Germovsek, Eva, et al.
Publicado: (2018)

Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors
por: Centanni, Maddalena, et al.
Publicado: (2019)

Population Pharmacokinetics and Pharmacodynamics of Oral Propranolol in Pediatric Patients With Infantile Hemangioma
por: Takechi, Tomoki, et al.
Publicado: (2018)

Semimechanistic pharmacokinetic–pharmacodynamic model of tripegfilgrastim for pediatric patients after chemotherapy
por: Lee, Soyoung, et al.
Publicado: (2023)

2946. Comparative Pharmacokinetics and Pharmacodynamics of Cefadroxil and Cephalexin for Pediatric Musculoskeletal Infections
por: Haynes, Andrew, et al.
Publicado: (2023)

Proteasome Inhibitors and Their Pharmacokinetics, Pharmacodynamics, and Metabolism
por: Wang, Jinhai, et al.
Publicado: (2021)

Effects of fenoldopam on kidney function parameters and its therapeutic efficacy in the management of acute kidney injury in dogs with heatstroke
por: Segev, Gilad, et al.
Publicado: (2018)

Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology
por: Bruin, Maaike A. C., et al.
Publicado: (2022)

Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen
por: de Vries Schultink, Aurelia H. M., et al.
Publicado: (2015)

Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate
por: Pautier, Patricia, et al.
Publicado: (2013)

The Pharmacokinetics and Pharmacodynamics of Iron Preparations
por: Geisser, Peter, et al.
Publicado: (2011)

Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide
por: Chen, Nianhang, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_n2iamhiquqdl4k3r401lf0dal1